

# Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study

Cumali Efe,<sup>1\*</sup> Renumathy Dhanasekaran ,<sup>2\*</sup> Craig Lammert ,<sup>3</sup> Berat Ebik,<sup>4</sup> Fatima Higuera-de la Tijera,<sup>5</sup> Costica Aloman,<sup>6</sup> Ali Rıza Calışkan,<sup>7</sup> Mirta Peralta,<sup>8,9</sup> Alessio Gerussi ,<sup>10,11</sup> Hatef Massoumi,<sup>12</sup> Andreea M. Catana,<sup>13</sup> Murat Torgutalp,<sup>14</sup> Tugrul Purnak,<sup>15</sup> Cristina Rigamonti ,<sup>16,17</sup> Andres Jose Gomez Aldana ,<sup>18</sup> Nidah Khakoo,<sup>19</sup> Hüseyin Kacmaz,<sup>7</sup> Leyla Nazal,<sup>20</sup> Shalom Frager ,<sup>12</sup> Nurhan Demir,<sup>21</sup> Kader Irak,<sup>22</sup> Zeynep Melekoğlu Ellik,<sup>23</sup> Yasemin Balaban ,<sup>24</sup> Kadri Atay,<sup>25</sup> Fatih Eren,<sup>26</sup> Laura Cristoferi ,<sup>10,11</sup> Ersin Batbay,<sup>1</sup> Álvaro Urzua ,<sup>27</sup> Romee Snijders,<sup>28,29</sup> Murat Kıyıcı,<sup>30</sup> Murat Akyıldız,<sup>31</sup> Nazım Ekin,<sup>4</sup> Rotonya M. Carr,<sup>32</sup> Murat Harputluoğlu,<sup>33</sup> Ibrahim Hatemi,<sup>34</sup> Manuel Mendizabal ,<sup>9,35</sup> Marcelo Silva,<sup>9,35</sup> Ramazan Idilman,<sup>23</sup> Marina Silveira,<sup>36</sup> Joost P.H. Drenth,<sup>28,29</sup> David N. Assis,<sup>36</sup> Einar Björnsson,<sup>37,38</sup> James L. Boyer,<sup>36</sup> Pietro Invernizzi,<sup>10,11</sup> Chyntia Levy,<sup>19</sup> Thomas D. Schiano ,<sup>39</sup> Ezequiel Ridruejo ,<sup>9,34,40\*\*</sup> and Staffan Wahlin  <sup>41\*\*</sup>

**BACKGROUND AND AIMS:** Data regarding outcome of COVID-19 in patients with autoimmune hepatitis (AIH) are lacking.

**APPROACH AND RESULTS:** We performed a retrospective study on patients with AIH and COVID-19 from 34 centers in Europe and the Americas. We analyzed factors associated with severe COVID-19 outcomes, defined as the need for mechanical ventilation, intensive care admission, and/or death. The outcomes of patients with AIH were compared to a propensity score–matched cohort of patients without AIH but with chronic liver diseases (CLD) and COVID-19. The frequency and clinical significance of new-onset liver injury (alanine aminotransferase > 2 × the upper limit of normal) during COVID-19 was also evaluated. We included 110 patients with AIH (80% female) with a median age of 49 (range, 18–85) years at COVID-19 diagnosis. New-onset liver injury was observed in 37.1% (33/89) of the patients. Use of antivirals was associated with liver injury ( $P = 0.041$ ; OR, 3.36; 95% CI, 1.05–10.78), while continued immunosuppression during COVID-19 was associated with a lower rate of liver injury ( $P = 0.009$ ; OR, 0.26; 95% CI, 0.09–0.71). The rates of severe COVID-19 (15.5% versus 20.2%,  $P = 0.231$ )

and all-cause mortality (10% versus 11.5%,  $P = 0.852$ ) were not different between AIH and non-AIH CLD. Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH ( $P < 0.001$ ; OR, 17.46; 95% CI, 4.22–72.13). Continuation of immunosuppression or presence of liver injury during COVID-19 was not associated with severe COVID-19.

**CONCLUSIONS:** This international, multicenter study reveals that patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH. Maintenance of immunosuppression during COVID-19 was not associated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19. (HEPATOLOGY 2021;73:2099–2109).

COVID-19, caused by the severe acute respiratory syndrome coronavirus 2, was first described in December 2019 in Wuhan, China.<sup>(1)</sup> Following this first report, it rapidly spread worldwide and caused an international pandemic. Most COVID-19 cases have mild symptoms, but the disease can result in

*Abbreviations:* AIH, autoimmune hepatitis; ALT, alanine aminotransferase; BMI, body mass index; CLD, chronic liver disease; IgG, immunoglobulin G; MMF, mycophenolate mofetil; 6-MP, 6-mercaptopurine; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; ULN, upper limit of normal.

Received December 23, 2020; accepted March 4, 2021.

Additional Supporting Information may be found at [onlinelibrary.wiley.com/doi/10.1002/hep.31797/supinfo](https://onlinelibrary.wiley.com/doi/10.1002/hep.31797/supinfo).

\*These authors contributed equally to this work as co-first authors.

\*\*These authors share senior authorship.

The Turkish Association for the Study of the Liver organized and supported the collection of data on Turkish patients. Supported by the Italian Ministry of University and Research, Department of Excellence project Precision Medicine Approach: Bringing Biomarker Research to Clinic (to A.G., L.C., and P.I.) and by Associazione Malattie Autoimmuni Fegat (AMAF) Monza and Associazione Italiana Ricerca Colangite Sclerosante (AIRCS) (to A.G., L.C., and P.I.).

hospitalization, progression to respiratory failure, and death.<sup>(2-4)</sup> Older age, cardiovascular diseases, chronic lung diseases, active cancer, obesity, and diabetes mellitus are risk factors for severe COVID-19 outcomes.<sup>(5)</sup> COVID-19 often affects the liver, and individuals with underlying chronic liver diseases (CLD) have high rates of hospitalization and mortality.<sup>(6,7)</sup>

Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease.<sup>(8)</sup> Corticosteroids alone or in combination with azathioprine is the standard therapy in AIH. Several alternative immunosuppressive

drugs, including tacrolimus, mycophenolate mofetil (MMF), methotrexate, 6-mercaptopurine (6-MP), rituximab, and infliximab, are used in patients who do not respond or are intolerant to standard therapy.<sup>(8,9)</sup> The majority of patients with AIH require lifelong immunosuppressive therapy, which may increase the risk of bacterial and viral infections.<sup>(8)</sup> Existing data regarding the clinical presentation and outcome of COVID-19 in patients with AIH are limited to small case series and expert opinions.<sup>(10,11)</sup> The stage of liver disease has been shown to be a risk factor, but it is

© 2021 by the American Association for the Study of Liver Diseases.  
View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com).  
DOI 10.1002/hep.31797

Potential conflict of interest: Dr. Invernizzi received grants from Intercept and Gilead. Dr. Carr received grants from Intercept and Merck. Dr. Silveira received grants from Novartis.

## ARTICLE INFORMATION:

From the <sup>1</sup>Department of Gastroenterology, Harran University Hospital, Şanlıurfa, Turkey; <sup>2</sup>Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford, CA; <sup>3</sup>Department of Medicine Indiana, University School of Medicine, Indianapolis, IN; <sup>4</sup>Department of Gastroenterology, Gazi Yaşargil Education and Research Hospital, Diyarbakir, Turkey; <sup>5</sup>Gastroenterology and Hepatology Unit, Hospital General de México, Mexico City, Mexico; <sup>6</sup>Section of Hepatology, Rush University Medical Center, Chicago, IL; <sup>7</sup>Department of Gastroenterology, Adiyaman University, Adiyaman, Turkey; <sup>8</sup>Hepatology Section, Hospital Francisco J Muñoz, Buenos Aires, Argentina; <sup>9</sup>Latin American Liver Research Educational and Awareness Network, Pilar, Argentina; <sup>10</sup>Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; <sup>11</sup>European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital, Monza, Italy; <sup>12</sup>Department of Medicine, Montefiore Medical Center, Bronx, NY; <sup>13</sup>Division of Gastroenterology/Hepatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; <sup>14</sup>Department of Gastroenterology, Infectious Diseases and Rheumatology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Berlin, Germany; <sup>15</sup>Division of Gastroenterology, Hepatology and Nutrition, McGovern Medical School, Houston, TX; <sup>16</sup>Department of Translational Medicine, Università del Piemonte Orientale UPO, Novara, Italy; <sup>17</sup>Division of Internal Medicine, "AOU Maggiore della Carità," Novara, Italy; <sup>18</sup>Gastroenterology and Hepatology Unit, Fundación Santa Fe de Bogotá y universidad de Los Andes, Bogotá, Colombia; <sup>19</sup>Division of Hepatology, University of Miami Miller School of Medicine, Miami, FL; <sup>20</sup>Gastroenterology and Hepatology Unit, Clínica Las Condes, Santiago de Chile, Chile; <sup>21</sup>Department of Gastroenterology, Haseki Training and Research Hospital, Istanbul, Turkey; <sup>22</sup>Department of Gastroenterology, SBU Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Turkey; <sup>23</sup>Department of Gastroenterology, Ankara University Medical Faculty, Ankara, Turkey; <sup>24</sup>Department of Gastroenterology, Faculty of Medicine, Hacettepe University, Ankara, Turkey; <sup>25</sup>Department of Gastroenterology, Mardin State Hospital, Mardin, Turkey; <sup>26</sup>Department of Gastroenterology, Ordu State Hospital, Ordu, Turkey; <sup>27</sup>Gastroenterology and Hepatology Unit, Hospital Clínico Universidad de Chile, Santiago de Chile, Chile; <sup>28</sup>Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; <sup>29</sup>European Reference Network on Hepatological Diseases (ERN RARE-LIVER); <sup>30</sup>Department of Gastroenterology, Medical Faculty, Uludag University, Bursa, Turkey; <sup>31</sup>Department of Gastroenterology, Koc University School of Medicine, Istanbul, Turkey; <sup>32</sup>Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA; <sup>33</sup>Department of Gastroenterology, İnönü University School of Medicine, Malatya, Turkey; <sup>34</sup>Department of Gastroenterology, Cerrahpaşa School of Medicine, İstanbul, Turkey; <sup>35</sup>Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Argentina; <sup>36</sup>Department of Medicine, Section of Digestive Diseases, Yale School of Medicine, New Haven, CT; <sup>37</sup>Department of Internal Medicine, Section of Gastroenterology, Landspítali University Hospital, Reykjavik, Iceland; <sup>38</sup>Faculty of Medicine, University of Iceland, Reykjavik, Iceland; <sup>39</sup>Division of Liver Diseases, Mount Sinai Medical Center, New York, NY; <sup>40</sup>Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina; <sup>41</sup>Hepatology Division, Department of Upper GI, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

## ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

Cumali Efe, M.D.  
Department of Gastroenterology, Harran University Hospital  
Şanlıurfa, Turkey

E-mail: [drcumi21@hotmail.com](mailto:drcumi21@hotmail.com)  
Tel.: +905055025596

unclear whether the type of underlying liver disease is a major contributing factor to poor outcomes with COVID-19. Specifically for AIH, immunosuppressive therapy enhances the risk of severe COVID-19. On the other hand, it may be argued that immunosuppression protects against the inappropriate immune response, or cytokine storm, which is a characteristic of severe COVID-19.<sup>(12)</sup>

The aims of this international multicenter study were to assess the clinical characteristics and outcomes of patients with AIH infected with COVID-19 and to explore the frequency and factors associated with new-onset liver injury and severe COVID-19 outcome in these patients.

## Materials and Methods

### STUDY DESIGN

We retrospectively evaluated data of patients with AIH who were diagnosed with COVID-19 between March 11 and November 12, 2020, from 34 centers in 10 countries. All participants independently identified patients and collected data from electronic health records and patients' follow-up charts. Patients with AIH who were older than 16 years at the time of COVID-19 with a diagnosis confirmed by a PCR-based test were included in the study. Patients with typical radiological findings but with negative PCR tests were not included. All patients with AIH, or overlap with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC), were diagnosed and treated according to international guidelines.<sup>(8,13)</sup>

The presence of cirrhosis was diagnosed based on standard imaging studies (elastography, ultrasound, CT, or MRI), liver tissue examination, or clinical findings of portal hypertension or its complications. Complete biochemical response was defined as normal alanine aminotransferase (ALT), aspartate aminotransferase (AST) and immunoglobulin G (IgG) levels. Partial response was defined as a decrease of ALT or AST to below 2 times the upper limit of normal (ULN), and nonresponse was defined as persistently elevated transaminase levels more than 2 times the ULN despite appropriate immunosuppressive therapy.<sup>(8,13)</sup> High alcohol consumption was

defined as more than 2 drinks/day for men and more than 1 drink/day for women.<sup>(14)</sup>

New-onset liver injury was defined as rising ALT values during COVID-19 and categorized as no or mild ( $< 2 \times$  ULN), moderate ( $2-5 \times$  ULN), or severe ( $>5 \times$  ULN). New-onset ALT  $> 2 \times$  ULN was used as the definition of liver injury for the study. Patients who were nonresponders to AIH therapy were excluded from new-onset liver injury analysis as they already had ALT  $> 2 \times$  ULN levels before the COVID-19 diagnosis. The cutoffs for normal values of ALT were considered 25 U/L for women and 35 U/L for men.<sup>(15)</sup> Severe COVID-19 infection was defined as a composite of intensive care unit (ICU) admission, ventilator use, and/or death, in line with previously reported COVID-19 data.<sup>(3)</sup> The Harran University Hospital of Şanlıurfa was the coordinating center (HRE ID 2020-00682), and the local ethical review boards of the participating centers approved the study.

### DATA COLLECTION

Collected patient data included general information on patients, autoimmune liver serology, types and doses of immunosuppression, the patient's AIH response status at last follow-up before COVID-19, and presence of cirrhosis. At the time of COVID-19 diagnosis, body mass index (BMI), clinical features, and comorbid conditions were recorded. Laboratory values at COVID-19 diagnosis and at peak/worst values any time in the first month of COVID-19 were used to evaluate liver injury. Any modification in the dose or type of immunosuppressive drugs during COVID-19, highest care level, hospitalization time, specific COVID-19 therapies, and patient outcomes, providing a minimum of 4 weeks after COVID-19, were recorded.

In order to determine how AIH impacts clinical outcomes with COVID-19, we compared AIH patients to a control group of patients with non-AIH CLD and COVID-19. To identify a control group, we used data from a multicenter, observational study of adult patients with CLD and PCR-confirmed COVID-19. More details regarding the inclusion and exclusion criteria of this cohort have been published.<sup>(7)</sup> Only patients without AIH from this cohort were included in the control group.

None of the patients in the control group were on immunosuppression.

## STATISTICAL ANALYSIS

Continuous variables are presented as mean with standard deviation or as median with range. The Student *t* test or the Mann-Whitney U test was used for comparisons, as appropriate depending on the distribution. Categorical variables are presented as numbers and percentages, and the chi-squared test was used for comparisons. Multivariable logistic regression analysis models were performed to predict the two major outcomes of the study (dependent variables): significant new-onset liver injury and severe COVID-19. According to the predefined statistical plan, we evaluated associations between each independent variable and outcome after having analyzed the number of outcome events. In addition to predefined sex and age in terms of their clinical relevance for the outcomes, independent variables with a statistically significant relationship ( $P < 0.1$ ) with dependent (outcome) variables in the univariate analysis were then included in the multivariable models. Hosmer-Lemeshow goodness-of-fit statistics were used to assess model fit.  $P < 0.05$  was considered to represent statistical significance.

We compared clinical outcomes of COVID-19 in patients with AIH and non-AIH CLD. We used propensity score analysis to identify a cohort of patients with non-AIH CLD and COVID-19 who were statistically

matched on a 1:2 basis using the nearest neighbor approach. We matched AIH and non-AIH for crucial variables which are known to impact clinical outcomes with COVID-19 including age, gender, presence of cirrhosis, diabetes mellitus, hypertension, and heart diseases.

## Results

### GENERAL CHARACTERISTICS OF THE STUDY POPULATION

Medical data of 115 patients with AIH who acquired COVID-19 were analyzed. Five patients were excluded: 3 patients had previously undergone liver transplantation, and 2 patients were concomitantly diagnosed with AIH and COVID-19 (Fig. 1). The final study group included 110 patients with AIH (80% female) with a median age of 49 (range, 18–85) years at COVID-19 infection. Four of these patients had been included in a previous study.<sup>(11)</sup> The general characteristics, clinical features, and outcomes of the patients are presented in Table 1. Twelve (10.9%) patients had overlap with PBC and 4 (3.6%), with PSC. Coexistence of other immune-mediated disorders was noted in 28 (25.5%) patients, including autoimmune thyroid diseases in 17 (15.4%) patients, inflammatory bowel diseases in 3 (2.7%), Sjögren syndrome in 2 (1.8%), systemic sclerosis in 2 (1.8%), rheumatoid arthritis in 2 (1.8%), systemic lupus erythematosus in 1 (0.9%), celiac disease in




FIG. 1. Study flowchart for patient inclusion.

**TABLE 1. Demographics, Clinical Features, and Outcomes of Study Population (n = 110)**

Region	
North America, n (%)	34 (30.9)
South America, n (%)	22 (20)
Europe, n (%)	54 (49.1)
Sex (female), n (%)	88 (80)
Overlap syndromes (PBC/PSC), n (%)	12/4 (10.9)/(3.6)
Concomitant autoimmune diseases, n (%)	28 (25.5)
ANA, n (%) <sup>*</sup>	77 (76.5)
SMA, n (%) <sup>†</sup>	46 (45.1)
LKM-1, n (%) <sup>‡</sup>	3 (3.8)
LC-1, n (%) <sup>§</sup>	3 (6.2)
SLA, n (%) <sup>  </sup>	2 (4.1)
AIH activity at last visit before COVID-19	
Complete response, n (%)	88 (80)
Partial response, n (%)	19 (17.3)
Nonresponse, n (%)	3 (2.7)
Presence of cirrhosis, n (%)	32 (29.1)
Features of patients with AIH at COVID-19 infection	
Age (years), mean (SD)	47.9 (15.8)
Time from AIH diagnosis, median (months)	60 (1-480)
BMI, kg/m <sup>2</sup> , mean (SD)	26.5 (5.3)
Comorbidities, (%)	53 (48.2)
Smoking	7 (6.4)
Alcohol	2 (1.8)
Hypertension	26 (23.6)
Diabetes	27 (24.5)
Coronary artery disease	5 (4.5)
Atrial fibrillation	2 (1.8)
Heart failure	2 (1.8)
Respiratory disease	9 (8.3)
Cancer history	5 (4.5)
Kidney insufficiency	1 (0.9)
Immunosuppressive therapy before COVID, n (%)	102 (92.7)
Azathioprine/6-MP	27 (24.5)
Azathioprine/6-MP + prednisolone/budesonide	39 (35.4)
Azathioprine/6-MP + tacrolimus	1 (0.9)
Azathioprine/6-MP + prednisolone/budesonide + tacrolimus	1 (0.9)
Azathioprine/6-MP + prednisolone/budesonide + infliximab	1 (0.9)
Azathioprine/6-MP + prednisolone/budesonide + vedolizumab	1 (0.9)
Prednisolone/budesonide	20 (18.1)
Prednisolone/budesonide + tacrolimus	2 (1.8)
Prednisolone/budesonide + MMF	4 (3.6)
Prednisolone/budesonide + methotrexate	1 (0.9)
Prednisolone/budesonide + tacrolimus +MMF	1 (0.9)
MMF	3 (2.7)
Sirolimus	1 (0.9)
Symptoms at presentation, n (%)	96 (87.3)

**TABLE 1. Continued**

Fever	65 (59.1)
Cough	68 (61.8)
Dyspnea	39 (35.5)
Headache	22 (20)
Fatigue and/or myalgia	65 (59.1)
Anosmia	19 (17.3)
Gastrointestinal symptoms, n (%)	30 (27.2)
Abdominal pain	11 (10)
Diarrhea	13 (11.8)
Nausea	7 (6.4)
Vomiting	11 (10)
Continued immunosuppression during COVID-19, n (%)	69 (62.7)
Antibiotic therapy during COVID-19, n (%)	40 (36.4)
Medical therapies for COVID-19, n (%)	67 (60.9)
Hydroxychloroquine	29 (26.4)
Antivirals	22 (20)
Favipiravir	17 (15.5)
Remdesivir	1 (0.9)
Lopinavir/ritonavir	4 (3.6)
High-dose steroids	15 (13.6)
Rituximab	1 (0.9)
Tocilizumab	1 (0.9)
Low-molecular weight heparin	26 (23.6)
Plasma exchange	3 (2.7)
Oxygen therapy, n (%)	42 (38.2)
Nasal cannula	25 (22.7)
Noninvasive ventilation/mechanical ventilation	9 (8.2)/8 (7.3)
New-onset liver injury during COVID-19, n (%) <sup>¶</sup>	33 (37.1)
Outcome of study population	
Hospitalized, n (%)	51 (46.4)
Intensive care admission, n (%)	15 (13.6)
Death, n (%)	11 (10)

<sup>\*</sup>ANA was available in 101 patients; BMI was available in 83.

<sup>†</sup>SMA was available in 101 patients.

<sup>‡</sup>LKM-1 was available in 80 patients.

<sup>§</sup>LC1-1 was available in 48 patients.

<sup>||</sup>SLA was available in 48 patients.

<sup>¶</sup>Liver injury was evaluated in 89 patients.

Abbreviations: ANA, antinuclear antibody; LC-1, liver-cytosol type 1; LKM-1, liver kidney microsome type 1; SLA, soluble liver antigen; SMA, smooth muscle antibody.

1 (0.9%), ankylosing spondylitis in 1 (0.9%), and anti-phospholipid syndrome in 1 (0.9%).

## AIH CHARACTERISTICS BEFORE COVID-19

At last follow-up before COVID-19 diagnosis, 88 (80%) patients were complete responders,

19 (17.3%) were partial responders, and 3 (2.7%) were nonresponders. Thirty-two (29.1%) patients with AIH had features of cirrhosis. A total of 53 (48.2%) patients had comorbid conditions; diabetes mellitus ( $n = 27$ , 24.5%) and hypertension ( $n = 26$ , 23.6%) were the most common. Seven (6.4%) patients reported active smoking, and 2 (1.8%) had high alcohol consumption. Five (4.5%) patients had a history of malignancy, two cases of which were active during COVID-19.

Most patients (92.7%) were on immunosuppressive therapy prior to the COVID-19 diagnosis. Eight patients (7.3%) were not on immunosuppressive therapy; 6 patients had withdrawn therapy (3 by themselves and 3 by a physician), 1 patient was a nonresponder to available therapies, and 1 had inactive ("burned-out") cirrhosis. At the time of COVID-19 diagnosis, 65 (59.1%) patients were on prednisone therapy (alone or in combination with other immunosuppressants) with a median dose of 5 (range, 2.5-60) mg/day. Among them, 25 (22.7%) patients were on prednisone  $\geq 10$  mg/day. The patients' immunosuppressive therapies are presented in Table 1.

## MANAGEMENT OF AIH DURING COVID-19

The majority of patients ( $n = 96$ , 87.3%) were symptomatic at the time of COVID-19 diagnosis; cough ( $n = 68$ , 61.8%) and fever ( $n = 65$ , 59.1%) were the most commonly reported symptoms. Gastrointestinal

symptoms (abdominal pain, diarrhea, nausea, and vomiting) were noted in 30 (27.2%) patients.

The dose or type of immunosuppression was modified in 33 (30%) patients during COVID-19 but remained unchanged in 69 (62.7%). General characteristics of the patients according to immunosuppressive therapy status are presented in Table 2. Among patients on azathioprine/6-MP monotherapy ( $n = 10$ ), doses were reduced in 3 and discontinued in 7. Among patients on steroid monotherapy ( $n = 2$ ), the dose was reduced in 1 and discontinued in 1. In patients treated with a combination of azathioprine/6-MP and steroids ( $n = 14$ ), the dose of only azathioprine/6-MP was reduced in 1 and discontinued in 5, the dose of only steroids was reduced in 5, while the doses of both azathioprine/6-MP and steroids were reduced in 1 and discontinued in 2. Azathioprine was discontinued and tacrolimus reduced in a patient who was treated with both drugs. In 1 patient who was on triple immunosuppression, azathioprine was discontinued, and both the steroid and tacrolimus doses were reduced. Among patients treated with MMF and steroids ( $n = 4$ ), only MMF was discontinued in 3, and both drugs were reduced in 1. The dose was reduced in a patient on MMF monotherapy.

Antibiotics were given to 40 (36.4%) patients during COVID-19 infection. Sixty-seven (60.9%) patients received specific therapy for COVID-19. Hydroxychloroquine ( $n = 29$ , 26.4%) and antivirals ( $n = 22$ , 20%) were the most commonly used therapies. High-dose steroids were given to 15 (13.6%) patients, and plasma exchange was performed in 3 (2.7%) patients. Tocilizumab and rituximab were used

**TABLE 2. Characteristics of Patients With AIH According to Immunosuppressive Therapy Status During COVID-19**

	Immunosuppression Unchanged ( $n = 69$ , %)	Immunosuppression Reduced/Stopped ( $n = 41$ , %)	<i>P</i>
Age > 65 (years)	13 (18.8)	4 (9.8)	0.278
Gender (female)	57 (82.6)	31 (75.6)	0.461
BMI > 30	8 (16.3)	8 (23.5)	0.572
Comorbidity	37 (53.6)	18 (43.9)	0.430
Cirrhosis	21 (30.4)	11 (26.8)	0.829
Remission before COVID-19	60 (87)	28 (68.3)	0.026
Symptoms at presentation	59 (85.5)	37 (90.2)	0.564
Treatment for COVID-19	43 (62.3)	24 (58.5)	0.840
New-onset liver injury*	12 (22.6)	21 (58.3)	0.001
Severe COVID-19	10 (14.5)	7 (17.1)	0.788
All-cause mortality	4 (5.8)	7 (17.7)	0.096

\*New-onset liver injury was evaluated in 89 patients.

in 1 (0.9%) patient each. The details of COVID-19 therapies are presented in Table 1.

## LIVER INJURY DURING COVID-19

New-onset liver injury was reported in 37.1% (33/89) of the patients: 16 (18%) had moderate and 17 (19.1%) had severe liver injury. New-onset liver injury was observed in 85.7% (6/7) of patients who were not on immunosuppression, in 51.7% (15/29) of patients whose immunosuppression was modified, and in 22.6% (12/53) of patients whose immunosuppression was unchanged during COVID-19. Predictors of liver injury are presented in Table 3. Multivariate regression analysis revealed that antivirals (defined in Table 1) were associated with new-onset liver injury ( $P = 0.041$ ; OR, 3.36; 95% CI, 1.05-10.78) and that continued immunosuppression during COVID-19 reduced the probability of liver injury ( $P = 0.009$ ; OR, 0.26; 95% CI, 0.09-0.71).

## OUTCOMES OF COVID-19 IN PATIENTS WITH AIH COMPARED TO NON-AIH CLD

When the outcomes of patients with AIH ( $n = 110$ ) were compared to a cohort of non-AIH patients with CLD ( $n = 220$ ) and COVID-19 (Supporting Table S1), no statistically significant differences were noted regarding the rates of all-cause mortality (10% versus 11.5%;  $P = 0.852$ ),

severe COVID-19 (15.5% versus 20.2%;  $P = 0.231$ ), need for supplemental oxygen (38.2% versus 42.2%;  $P = 0.553$ ), and hospitalization (46.4% versus 50.0%;  $P = 0.560$ ) (Fig. 2).

Seventeen AIH patients had severe COVID-19, and 11 patients died due to COVID-19. Predictors of severe outcomes in patients with AIH are presented in Table 4. After adjusting for age, gender, coexistence of PBC/PSC or extrahepatic autoimmune diseases, and AIH therapy response, the presence of cirrhosis was independently associated with severe COVID-19 ( $P < 0.001$ ; OR, 17.46; 95% CI, 4.22-72.13). Patients with AIH and comorbid conditions (defined in Table 1) tended to have severe COVID-19 infection ( $P = 0.06$ ; OR, 4.16; 95% CI, 0.94-18.36). Presence of liver injury and continued immunosuppression during COVID-19 were not associated with severe COVID-19.


## Discussion

In this international multicenter study, we evaluated the clinical presentation, laboratory features, and outcomes of COVID-19 in patients with AIH. In our study population, 37.1% of the patients developed new-onset liver injury during COVID-19. Among 110 patients with AIH, 15.5% had severe COVID-19, and 10% died. Our data show that (1) the overall outcome of COVID-19 was favorable in

**TABLE 3. Univariate and Multivariate Analyses of New-Onset Liver Injury in Patients With AIH and COVID-19**

	Univariate Analysis			Multivariate Analysis		
	OR	95% CI	<i>P</i>	OR	95% CI	<i>P</i>
Sex (female)	1.21	0.37-3.93	0.742	1.85	0.42-8.05	0.407
Age (>65 years)	0.56	0.16-1.94	0.364	0.76	0.18-3.10	0.704
BMI (>30)	2.05	0.62-6.75	0.235			
Complete response to therapy	0.27	0.09-0.85	0.025	0.27	0.06-1.15	0.077
Cirrhosis	1.05	0.42-2.63	0.908			
Comorbidities	1.06	0.44-2.51	0.890			
Immunosuppression maintenance	0.20	0.08-0.52	0.001	0.26	0.09-0.71	0.009
Antibiotics	1.64	0.68-3.91	0.263			
Antivirals	3.00	1.06-8.49	0.039	3.36	1.05-10.78	0.041
Hydroxychloroquine	0.86	0.33-2.23	0.757			
High-dose steroid	0.82	0.25-2.65	0.742			
O <sub>2</sub> therapy (any)	2.56	1.06-6.20	0.037	2.23	0.81-6.13	0.118

Comorbidities and antivirals are presented in Table 1.



**FIG. 2.** Clinical outcomes of COVID-19 in patients with AIH compared to non-AIH CLD. All-cause mortality (10% versus 11.5%), severe COVID-19 (15.5% versus 20.2%), need for supplemental oxygen (38.2% versus 42.2%), and hospitalization (46.4% versus 50%). *P* = nonsignificant for all comparisons. Abbreviation: ns, nonsignificant.

patients without cirrhosis, (2) ongoing immunosuppression was not associated with increased risk of severe COVID-19, and (3) maintenance of immunosuppression was associated with a lower risk for new-onset liver injury.

We found similar rates of severe COVID-19 outcome and mortality in patients with AIH and a matched control group of non-AIH CLD and COVID-19. Among patients with AIH, those with cirrhosis had higher risk for severe COVID-19 outcomes (43.8% versus 3.9%). Overall mortality was also significantly higher in patients with cirrhosis than those without (31.3% versus 1.3%). In line with

our results, other studies have reported 30%-34% mortality rates in patients with cirrhosis.<sup>(16,17)</sup> These results suggest that, regardless of etiology, cirrhosis is a strong predictor of worse prognosis in patients with COVID-19. Consistent with previous reports,<sup>(5)</sup> patients with AIH and comorbid conditions in our study tended to have severe COVID-19.

New-onset liver injury was observed in 37.1% during COVID-19. Other studies have reported the rate to be 27.4% in a general population,<sup>(18)</sup> 34.6% in liver transplant recipients, and 47.5% in patients with CLD.<sup>(19)</sup> Liver injury was found to be a predictor of poor outcome in these studies.<sup>(7,18,19)</sup> In our AIH cohort, liver injury was not associated with adverse COVID-19 outcomes. There are several possible causes of liver injury in COVID-19, and all causes probably do not carry the same mortality risk.<sup>(18,20)</sup>

Patients who develop hepatocyte necrosis induced by systemic inflammatory response syndrome or ischemic injury due to circulatory or respiratory failure may have a higher mortality risk compared to those who have a drug-induced liver injury or develop an AIH relapse. The similar outcomes of patients with and without liver injury in our study might be explained by the likely incidence of AIH relapse or drug-induced liver injury, both manageable causes of liver injury.

Relapse of AIH following infection is a well-known phenomenon.<sup>(14)</sup> COVID-19 can trigger hyperstimulation of the immune system, an event associated with high serum levels of inflammatory cytokines and chemokines.<sup>(12)</sup> Four patients with AIH and

**TABLE 4. Univariate and Multivariate Analyses for Predictors of Severe COVID-19 in Patients With AIH**

	Univariate Analysis			Multivariate Analysis		
	OR	95% CI	<i>P</i>	OR	95% CI	<i>P</i>
Sex (female)	1.19	0.31-4.59	0.792	2.20	0.44-10.82	0.330
Age (>65 years)	2.81	0.84-9.40	0.093	1.03	0.23-4.48	0.964
Overlap of PBC/PSC	1.31	0.33-5.23	0.694			
Extrahepatic autoimmune diseases	1.26	0.40-3.98	0.684			
BMI (>30)	1.94	0.44-8.54	0.378			
Comorbidities	6.46	1.73-24.02	0.005	4.16	0.94-18.36	0.060
Prednisolone (≥10 mg)	2.12	0.70-6.48	0.192			
Complete response to therapy	0.53	0.16-1.72	0.297			
Cirrhosis	19.44	5.04-74.92	<0.001	17.46	4.22-72.13	<0.001
Immunosuppression maintenance	0.82	0.28-2.36	0.718			
Acute liver injury	1.67	0.57-4.86	0.346			

nonsevere COVID-19 had new-onset liver injury along with high IgG levels, thus suggesting that they experienced AIH relapse rather than COVID-19-induced liver injury (Table 5). Development of various inflammatory or autoimmune conditions has been reported during or shortly after COVID-19.<sup>(12,21)</sup> Some case reports have suggested that AIH presents for the first time during COVID-19.<sup>(21,22)</sup> In fact, 2 patients in our cohort (both excluded) did receive their initial diagnosis of AIH during COVID-19. Overall, our results suggest that COVID-19 may be associated with new onset or flare of AIH, especially in patients whose immunosuppression is reduced.

A lack of clear data has made it difficult to make definitive recommendations for management of immunosuppression during COVID-19. In our study, the doses and types of immunosuppression were continued unchanged in 62.7% of the patients when they acquired COVID-19, and this was not associated with adverse COVID-19 outcomes. Two previous studies<sup>(19,23)</sup> also reported that continued immunosuppression did not increase the risk of severe COVID-19 in liver transplant recipients; only MMF usage was linked to severe COVID-19 outcome.<sup>(23)</sup> In our study, MMF was discontinued or reduced in 62.5% (5/8) of the patients who were on this drug. Also, therapy with prednisone ( $\geq 10$  mg/day) was associated with higher hospitalization rates in a rheumatology setting,<sup>(24)</sup> and similar results were also reported in patients with inflammatory bowel disease.<sup>(25)</sup> However, the rates of severe COVID-19 were not different in patients with AIH who were on prednisone  $\geq 10$  mg/day compared to patients on  $< 10$  mg/day (24 versus 12.9%,  $P = 0.211$ ). Due to the low number of patients who were on  $\geq 10$  mg/day prednisone or MMF therapy, we

cannot draw definitive conclusions about the associated risks. Of note, patients whose immunosuppressive therapy was modified during COVID-19 experienced higher rates of liver injury or AIH relapse than those in whom immunosuppressive therapy was not modified. Relapse of AIH due to reduction or withdrawal of immunosuppression during COVID-19 represents diagnostic and therapeutic challenges. Elevated aminotransferases may be misinterpreted as a marker for severe COVID-19 and lead to unnecessary hospitalizations. Induction therapy to achieve AIH remission requires higher doses of immunosuppression, which may adversely affect the outcome of COVID-19. Our results support maintaining immunosuppressive therapy during COVID-19.

We acknowledge that the retrospective nature of our study is a main limitation. However, given the unprecedented nature of the pandemic and the low prevalence of AIH, we believe that our study offers valuable insights into the management of these patients. Another limitation is the possibility of selection bias because asymptomatic patients and those with mild disease were likely not included in our study. We have, however, included both outpatients and inpatients, and  $> 50\%$  our study population were outpatients. We also observed that some of the hospitalized patients had a short hospital stay. Because patients with AIH were immunosuppressed or had concomitant comorbid conditions and because of a lack of information about appropriate use of immunosuppressive therapy during COVID-19, it is possible that patients were admitted out of caution and that hospitalization may not necessarily reflect the severity of COVID-19. We also found that management and therapeutic strategies for COVID-19 vary significantly between centers and countries. To

**TABLE 5. Characteristics of Patients With AIH and Features of Disease Relapse During COVID-19**

Case	Sex	Age at COVID-19	Diagnosis	Response at Last Visit	Therapy During COVID-19	Care for COVID-19	ALT/IgG ( $\times$ ULN)	Management/Response
1	F	60	AIH	Complete	Azathioprine, 50 mg/day, Prednisolone, 5 mg/day	Home	6.9/1.1	Azathioprine and prednisolone increased/Yes
2	F	52	AIH	Complete	MMF, 1,000 mg/day, Prednisolone, 10 mg/day	Hospital, 5 days, no O <sub>2</sub> therapy	6.8/1.7	MMF switched to tacrolimus/Yes
3	F	44	AIH	Complete	In remission without therapy	Home	4.3/1.2	Azathioprine and prednisolone added/Yes
4	F	51	AIH/PBC	Complete	Prednisolone, 5 mg/day, UDCA, 750 mg/day	Hospital, 6 days, nasal O <sub>2</sub>	4.8/1.2	Prednisolone increased/Yes

Abbreviation: UDCA, ursodeoxycholic acid.

overcome these limitations, we used widely accepted clinical endpoints of severe COVID-19 infection like ICU admission, need for mechanical ventilation, and/or death.<sup>(3,23,25)</sup>

Our study also has several strengths. We derived data from many hepatology centers across Europe and the Americas, and this represents the largest cohort describing COVID-19 in AIH to date. Moreover, we collected detailed information on immunosuppression changes during the course of COVID-19, allowing us to discern the effects of dose reductions and modifications on clinical outcomes. Lastly, we compared the AIH cohort with a matched non-AIH cohort, which allowed us to examine the impact of AIH itself on clinical outcomes of COVID-19.

In conclusion, this large multicenter study of patients with AIH and COVID-19 found overall mortality and severe COVID-19 rates of 10% and 15.5%, respectively. Patients with AIH, despite being immunosuppressed, did not experience worse clinical outcomes with COVID-19 than patients with non-AIH CLD. Presence of cirrhosis was the strongest predictor of severe COVID-19, and the overall outcome of COVID-19 was favorable in patients with noncirrhotic AIH. Maintenance of immunosuppression was associated with lower risk of new-onset liver injury. We recommend that immunosuppression not be decreased or discontinued upon diagnosis of COVID-19.

*Author Contributions:* C.E., T.D.S., S.W., R.D., and E.R. were responsible for the study concept. C.E., M.T., R.D., B.E., A.R.Ç., S.W., and E.R. were responsible for data analysis. M.T. was responsible for statistical analysis. C.E., T.D.S., R.D., E.R., P.I., and S.W. were responsible for data interpretation and preparing the manuscript for final submission. All authors contributed data and approved final manuscript.

## REFERENCES

- Morens DM, Daszak P, Taubenberger JK. Escaping Pandora's box—another novel coronavirus. *N Engl J Med* 2020;382:1293-1295.
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 2020;7:1239-1242.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020;382:1708-1720.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA* 2020;12:1775-1776.
- Yapali S. What hepatologists need to know about COVID-19? *Hepatology Forum* 2020;2:41-43.
- Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, et al. Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study. *Clin Gastroenterol Hepatol* 2020 Sep 17. doi: <https://doi.org/10.1016/j.cgh.2020.09.027>. [Epub ahead of print]
- Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. *HEPATOLOGY* 2020;72:671-722.
- Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis DN, et al. Immunosuppressive treatment regimens in autoimmune hepatitis: systematic reviews and meta-analyses supporting American Association for the Study of Liver Diseases guidelines. *HEPATOLOGY* 2020;72:753-769.
- Kardashian A, Wilder J, Terrault NA, Price JC. Addressing social determinants of liver disease during the COVID-19 pandemic and beyond: a call to action. *HEPATOLOGY* 2021;73:811-820.
- Gerussi A, Rigamonti C, Elia C, Cazzagon N, Floreani A, Pozzi R, et al. Coronavirus disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. *Hepatol Commun* 2020;4:1257-1262.
- Rodríguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. *J Autoimmun* 2020;114:102506.
- European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. *J Hepatol* 2015;63:971-1004.
- Zakhari S, Li TK. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. *HEPATOLOGY* 2007;46:2032-2039.
- Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *HEPATOLOGY* 2018;67:1560-1599.
- Bajaj JS, Garcia-Tsao G, Biggins S, Kamath PS, Wong F, McGeorge S, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. *Gut* 2021;70:531-536.
- Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. *J Hepatol* 2020;73:1063-1071.
- Phipps MM, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, et al. Acute liver injury in COVID-19: prevalence and association with clinical outcomes in a large US cohort. *HEPATOLOGY* 2020;72:807-817.
- Rabiee A, Sadowski B, Adeniji N, Perumalswami P, Nguyen V, Moghe A, et al. Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): US multicenter experience. *HEPATOLOGY* 2020;72:1900-1911.
- Saviano A, Wrensch F, Ghany MG, Baumert TF. Liver disease and COVID-19: from pathogenesis to clinical care. *HEPATOLOGY* 2020 Dec 17. doi: <https://doi.org/10.1002/hep.31684>. [Epub ahead of print]

- 21) Marabotto E, Ziola S, Sheijani AD, Giannini EG. COVID-19 and liver disease: not all evil comes to harm. *Liver Int* 2021;41:237-238.
- 22) Hong J, Chopra S, Kahn JA, Kim B. Autoimmune hepatitis triggered by COVID-19. *HEPATOLOGY* 2020;130: Poster 260A.
- 23) **Colmenero J, Rodríguez-Perálvarez M**, Salcedo M, Arias-Milla A, Muñoz-Serrano A, Graus J, et al. Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients. *J Hepatol.* 2021;74:148-155.
- 24) **Gianfrancesco M, Hyrich KL**, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis* 2020;79:859-866.

- 25) **Brenner EJ, Ungaro RC**, Geary RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. *Gastroenterology* 2020;159:481-491.e3.

Author names in bold designate shared first authorship.

## Supporting Information

Additional Supporting Information may be found at [onlinelibrary.wiley.com/doi/10.1002/hep.31797/supinfo](https://onlinelibrary.wiley.com/doi/10.1002/hep.31797/supinfo).